WO2008114859A1 - ピラゾール誘導体を含有する医薬組成物 - Google Patents

ピラゾール誘導体を含有する医薬組成物 Download PDF

Info

Publication number
WO2008114859A1
WO2008114859A1 PCT/JP2008/055223 JP2008055223W WO2008114859A1 WO 2008114859 A1 WO2008114859 A1 WO 2008114859A1 JP 2008055223 W JP2008055223 W JP 2008055223W WO 2008114859 A1 WO2008114859 A1 WO 2008114859A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
composition containing
preparation
Prior art date
Application number
PCT/JP2008/055223
Other languages
English (en)
French (fr)
Inventor
Toshiro Sakai
Atsushi Sakurai
Koji Kitada
Kazuto Okimoto
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to JP2009505254A priority Critical patent/JPWO2008114859A1/ja
Publication of WO2008114859A1 publication Critical patent/WO2008114859A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

　本発明は、溶出特性の改善した化合物（Ｉ）又はその製薬学的に許容される塩を含む製剤を提供することを目的とする。また、本発明の別の課題は、溶出特性の改善した化合物（Ｉ）又はその製薬学的に許容される塩を含み、かつ、安定な製剤の提供することを目的とする。 　本発明は、化合物（Ｉ）又はその製薬学的に許容される塩の固体分散体と、ＨＰＭＣを含有する組成物を用いることによって、可溶化した化合物（Ｉ）又はその製薬学的に許容される塩の溶液中における再析出を抑制することにより、化合物（Ｉ）又はその許容される塩の過飽和状態を維持し、及び消化管からの吸収性の向上を可能にしたものである。また、化合物（Ｉ）又はその製薬学的に許容される塩の固体分散体とＨＰＭＣとの間に、錠剤にコーティング可能な、酸性から中性付近の水あるいは緩衝液中で溶解あるいは膨潤する物質を含有することによって、上記過飽和維持効果を持たせるとともに、安定な製剤の提供を可能にしたものである。
PCT/JP2008/055223 2007-03-22 2008-03-21 ピラゾール誘導体を含有する医薬組成物 WO2008114859A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009505254A JPWO2008114859A1 (ja) 2007-03-22 2008-03-21 ピラゾール誘導体を含有する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-074893 2007-03-22
JP2007074893 2007-03-22

Publications (1)

Publication Number Publication Date
WO2008114859A1 true WO2008114859A1 (ja) 2008-09-25

Family

ID=39765959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/055223 WO2008114859A1 (ja) 2007-03-22 2008-03-21 ピラゾール誘導体を含有する医薬組成物

Country Status (2)

Country Link
JP (1) JPWO2008114859A1 (ja)
WO (1) WO2008114859A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011201830A (ja) * 2010-03-26 2011-10-13 Taiyo Yakuhin Kogyo Kk フロセミド製剤
JP2016013980A (ja) * 2014-07-01 2016-01-28 大原薬品工業株式会社 テルミサルタン含有フィルムコーティング錠剤
JP2017511313A (ja) * 2014-03-26 2017-04-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法
WO2019098259A1 (ja) * 2017-11-17 2019-05-23 塩野義製薬株式会社 光安定性および溶出性に優れた医薬製剤
JP2020117476A (ja) * 2019-01-25 2020-08-06 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法
JPWO2019221215A1 (ja) * 2018-05-18 2021-05-27 ニプロ株式会社 ルビプロストン含有粒子状医薬組成物
US11406600B2 (en) 2017-11-22 2022-08-09 Sawai Pharmaceutical Co., Ltd. Anhydrous dasatinib-containing preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees
WO1997034601A1 (fr) * 1996-03-18 1997-09-25 Eisai Co., Ltd. Compositions medicamenteuses a solubilite amelioree
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
WO2001045705A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
WO2003000294A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
WO2004050632A1 (en) * 2002-12-02 2004-06-17 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives useful as cox-i inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees
WO1997034601A1 (fr) * 1996-03-18 1997-09-25 Eisai Co., Ltd. Compositions medicamenteuses a solubilite amelioree
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
WO2001045705A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
WO2003000294A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
WO2004050632A1 (en) * 2002-12-02 2004-06-17 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives useful as cox-i inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUSHIDA I. ET AL.: "Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 91, no. 1, 2002, pages 258 - 266 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011201830A (ja) * 2010-03-26 2011-10-13 Taiyo Yakuhin Kogyo Kk フロセミド製剤
JP2017511313A (ja) * 2014-03-26 2017-04-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法
JP2016013980A (ja) * 2014-07-01 2016-01-28 大原薬品工業株式会社 テルミサルタン含有フィルムコーティング錠剤
WO2019098259A1 (ja) * 2017-11-17 2019-05-23 塩野義製薬株式会社 光安定性および溶出性に優れた医薬製剤
JPWO2019098259A1 (ja) * 2017-11-17 2019-12-12 塩野義製薬株式会社 光安定性および溶出性に優れた医薬製剤
US11406600B2 (en) 2017-11-22 2022-08-09 Sawai Pharmaceutical Co., Ltd. Anhydrous dasatinib-containing preparation
JPWO2019221215A1 (ja) * 2018-05-18 2021-05-27 ニプロ株式会社 ルビプロストン含有粒子状医薬組成物
JP2020117476A (ja) * 2019-01-25 2020-08-06 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法
JP7262005B2 (ja) 2019-01-25 2023-04-21 日本ジェネリック株式会社 シロドシン含有固形組成物及びその製造法

Also Published As

Publication number Publication date
JPWO2008114859A1 (ja) 2010-07-08

Similar Documents

Publication Publication Date Title
WO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
WO2007041156A3 (en) Antibiotic formulations, unit doses, kits, and methods
WO2008010921A3 (en) Modulators of pharmacokinetic properties of therapeutics
EP2076244A4 (en) AQUEOUS SYSTEMS FOR THE PREPARATION OF LIPID-BASED PHARMACEUTICAL COMPOUNDS AND THEIR COMPOSITIONS, METHODS AND USES
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
TW200716202A (en) Pediatric formulation of topiramate
IL195732A (en) Pharmaceutical compounds containing passoterodine, their use and method for their preparation
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2008129517A3 (en) A stabilized delayed release pharmaceutical composition of rabeprazole
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
EP2196206B8 (en) Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient
MY163762A (en) Therapeutic agent for chronic renal failure
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
HUP0600293A2 (en) Zinc salt of rosuvastatine, process for its preparation and pharmaceutical compositions containing it
EP1968606A4 (en) PREPARATION OF PHARMACEUTICAL SALTS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC ACID
WO2007118873A3 (en) Polymorphs of atorvastatin sodium and magnesium salts
EP1883619B8 (en) Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
EP1935417A4 (en) COMPOSITION FOR USE IN PREVENTING A HYPOGLYCEMIC STATE
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2008104852A3 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2010013835A3 (en) Solid pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08722587

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009505254

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08722587

Country of ref document: EP

Kind code of ref document: A1